On June 7, 2018 – Health Canada issued a warning regarding the possible risk of neural tube defects associated with dolutegravir use during early pregnancy. This warning is based on preliminary findings from an observational study in Botswana, which identified 4 infants with neural tube defects born to women who had been treated with dolutegravir at the time of conception.
For more information: Click here to view the Health Canada advisory
In collaboration with the BC Centre for Excellence in HIV/AIDS, the Oak Tree Clinic at BC Women’s Hospital and Health Centre has developed Dolutegravir prescribing guidelines for pregnancy and women of reproductive potential.
Amendment: On July 31, 2019, the Oak Tree Clinic guidelines were updated to reflect new information. Click here to view the most recent updates to the Oak Tree Clinic resources for healthcare providers (scroll down the page to Antiretroviral Drug Information)